BTAI insider transaction filings
BioXcel Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen BTAI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Atkins Susan E. — Director | 1 | — | — | 1 |
Recent Form 4 filings — BioXcel Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Atkins Susan E. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 219 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 17,500 · Sale (S): 6,560 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 49,758 · Sale (S): 19,419 @ $1.09 · Option exercise (M): 49,758 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 18,000 · Option exercise (M): 18,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Laumas Sandeep — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Bray June — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | MACK DAVID J. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Votruba Michal — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Patni Rajiv — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | MUELLER PETER — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | MILLER MICHAEL PATRICK — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Yocca Frank — Chief Scientific Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Mehta Vimal — CEO and President, Director | Grant/award (A): 199,032 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Rodriguez Javier — See Remarks | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Steinhart Richard I — Chief Financial Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,694 · Option exercise (M): 1,694 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,694 · Option exercise (M): 1,694 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Mehta Vimal — CEO and President, Director | Option exercise (M): 163 · Option exercise (M): 219 · Option exercise (M): 163 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Rodriguez Javier — See Remarks | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Yocca Frank — Chief Scientific Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Rodriguez Javier — See Remarks | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Yocca Frank — Chief Scientific Officer | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Mehta Vimal — CEO and President, Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Steinhart Richard I — Chief Financial Officer | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-07-31 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | Mehta Vimal — CEO and President, Director | Grant/award (A): 15,625 | EDGAR |
| 2025-07-22 | 4 | Yocca Frank — Chief Scientific Officer | Grant/award (A): 4,375 | EDGAR |
| 2025-07-22 | 4 | Rodriguez Javier — See Remarks | Grant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | Steinhart Richard I — Chief Financial Officer | Grant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | MACK DAVID J. — Director | Option exercise (M): 1,693 · Option exercise (M): 1,693 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Steinhart Richard I — Chief Financial Officer | Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0 | EDGAR |
Recent 8-K events — BioXcel Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-01 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership | EDGAR |
| 2026-08-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BTAI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →